Maximilian Gahr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3057738/publications.pdf

Version: 2024-02-01

		623734	642732
52	669	14	23
papers	citations	h-index	g-index
Γ0	Γ0	Ε0	0.42
58	58	58	843
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pregabalin abuse and dependence in Germany: results from a database query. European Journal of Clinical Pharmacology, 2013, 69, 1335-1342.	1.9	109
2	Concerns About Pregabalin. Journal of Addiction Medicine, 2013, 7, 147-149.	2.6	51
3	Cerebral amyloidal angiopathyâ€"A disease with implications for neurology and psychiatry. Brain Research, 2013, 1519, 19-30.	2.2	36
4	Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reactions. Psychiatry Research, 2014, 215, 252-254.	3.3	31
5	Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks. Current Neuropharmacology, 2014, 12, 387-398.	2.9	29
6	The state of mental health care in China. Asian Journal of Psychiatry, 2022, 69, 102975.	2.0	24
7	Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity. Current Drug Metabolism, 2015, 15, 694-702.	1.2	23
8	Safety of Electroconvulsive Therapy in the Presence of Cranial Metallic Objects. Journal of ECT, 2014, 30, 62-68.	0.6	22
9	Paliperidone extended-release: does it have a place in antipsychotic therapy?. Drug Design, Development and Therapy, 2011, 5, 125.	4.3	20
10	"Krokodilâ€â€"Revival of an Old Drug with New Problems. Substance Use and Misuse, 2012, 47, 861-863.	1.4	20
11	Self-mutilation induced by psychotropic substances: A systematic review. Psychiatry Research, 2012, 200, 977-983.	3.3	18
11		3.3 3.3	18
	200, 977-983. Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative		
12	Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry, 2020, 53, 51-59. Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Research, 2015, 229,	3.3	18
12 13	Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry, 2020, 53, 51-59. Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Research, 2015, 229, 257-263. Relation of Promoter Methylation of the Oxytocin Gene to Stressful Life Events and Depression	3.3	18
12 13 14	Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry, 2020, 53, 51-59. Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Research, 2015, 229, 257-263. Relation of Promoter Methylation of the Oxytocin Gene to Stressful Life Events and Depression Severity. Journal of Molecular Neuroscience, 2020, 70, 201-211. Psychological Distress, Fear and Coping Strategies During the Second and Third Waves of the	3.3 3.3 2.3	18 17 17
12 13 14	Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry, 2020, 53, 51-59. Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Research, 2015, 229, 257-263. Relation of Promoter Methylation of the Oxytocin Gene to Stressful Life Events and Depression Severity. Journal of Molecular Neuroscience, 2020, 70, 201-211. Psychological Distress, Fear and Coping Strategies During the Second and Third Waves of the COVID-19 Pandemic in Southern Germany. Frontiers in Psychiatry, 2022, 13, 860683. Linking Annual Prescription Volume of Antidepressants to Corresponding Web Search Query Data.	3.3 2.3 2.6	18 17 17

#	Article	IF	CITATIONS
19	Intoxications with the monoamine oxidase inhibitor tranylcypromine: An analysis of fatal and non-fatal events. European Neuropsychopharmacology, 2013, 23, 1364-1372.	0.7	10
20	Mild Hypothermia in a Child with Low-Dose Risperidone. Zeitschrift FÜr Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2017, 45, 335-337.	0.7	10
21	Abuse liability of centrally acting non-opioid analgesics and muscle relaxants – a brief update based on a comparison of pharmacovigilance data and evidence from the literature. International Journal of Neuropsychopharmacology, 2014, 17, 957-959.	2.1	9
22	Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre. Journal of Clinical Pharmacology, 2015, 55, 768-773.	2.0	9
23	Rediscovering Psilocybin as an Antidepressive Treatment Strategy. Pharmaceuticals, 2021, 14, 985.	3.8	8
24	Neuroleptic malignant syndrome with aripiprazole in Huntington's disease. Movement Disorders, 2010, 25, 2475-2476.	3.9	7
25	Cognitive Impairment and Abnormal Behaviour Related to Ring Chromosome 20 Aberration. Journal of Autism and Developmental Disorders, 2012, 42, 1146-1148.	2.7	7
26	Periventricular white matter lesion and incomplete MRZ reaction in a male patient with anti-N-methyl-D-aspartate receptor encephalitis presenting with dysphoric mania. BMJ Case Reports, 2015, 2015, bcr2014209075-bcr2014209075.	0.5	7
27	Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany. European Journal of Clinical Pharmacology, 2021, 77, 767-775.	1.9	7
28	Incidence of inpatient cases with mental disorders due to use of cannabinoids in Germany: a nationwide evaluation. European Journal of Public Health, 2022, 32, 239-245.	0.3	7
29	Dependence on Flupirtine. Journal of Clinical Pharmacology, 2013, 53, 1003-1004.	2.0	6
30	From benzodiazepine to pregabalin dependence: Different agents, similar problems. Indian Journal of Psychiatry, 2015, 57, 111.	0.7	6
31	Somatization Disorder Treated With Electroconvulsive Therapy. Journal of ECT, 2011, 27, 266-267.	0.6	5
32	Pregabalin and addiction: lessons from published cases. Journal of Substance Use, 2014, 19, 448-449.	0.7	5
33	Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. Journal of Substance Abuse Treatment, 2017, 74, 7-15.	2.8	5
34	Depressive Disorder With Panic Attacks After Replacement of an Intrauterine Device Containing Levonorgestrel: A Case Report. Frontiers in Psychiatry, 2020, 11, 561685.	2.6	5
35	Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey. Expert Opinion on Drug Safety, 2021, 20, 979-985.	2.4	5
36	Survival of Very High Blood Alcohol Concentration Without Consequential Damage in a Patient Without a Previous Substance Use Disorder. Journal of Forensic Sciences, 2016, 61, 1155-1157.	1.6	4

#	Article	IF	CITATIONS
37	Protracted delirium with Sheehan's syndrome. Acta Neuropsychiatrica, 2012, 24, 183-185.	2.1	3
38	Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. International Journal of Molecular Sciences, 2017, 18, 101.	4.1	3
39	Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions. Brain Sciences, 2019, 9, 322.	2.3	3
40	Lithium Therapy Associated With Renal and Upper and Lower Urinary Tract Tumors. Journal of Clinical Psychopharmacology, 2019, 39, 530-532.	1.4	3
41	Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine. Frontiers in Psychiatry, 2020, 11, 32.	2.6	3
42	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. Drugs - Real World Outcomes, 2021, 8, 547-554.	1.6	3
43	Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection. Frontiers in Psychiatry, 2021, 12, 727687.	2.6	3
44	Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report. Journal of Medical Case Reports, 2012, 6, 49.	0.8	2
45	Rapid relapse in depression following initialization of oral contraception with ethinyl estradiol and chlormadinone acetate. General Hospital Psychiatry, 2014, 36, 230.e1-230.e2.	2.4	2
46	First-Episode Psychosis Possibly due to Roxithromycin-Related Inhibition of Metabolization of Tetrahydrocannabinol. Journal of Clinical Psychopharmacology, 2017, 37, 369-370.	1.4	2
47	Psychiatrists' and dentists' knowledge and attitudes regarding adverse drug reactions of psychotropic drugs. Psychiatry Research, 2018, 266, 323-327.	3.3	2
48	Takotsubo Cardiomyopathy With Inconspicuous Initial Electrocardiogram: A Potentially Serious Cardiac Pathology Related to Emotional Stress. Frontiers in Psychiatry, 2019, 10, 308.	2.6	2
49	Non-suicidal self-injury by intravenous application of nicotine in a patient with borderline personality disorder resulting in substance dependence. Addiction, 2011, 106, 1186-1187.	3.3	1
50	Electroconvulsive therapy in patients with diagnoses other than major depression and/or difficult characteristics: A combined psychiatric–anesthesiological approach based on a retrospective chart analysis. Psychiatry Research, 2013, 210, 159-165.	3.3	1
51	Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants. primary care companion for CNS disorders, The, 2017, 19, .	0.6	1
52	Harmonization of summaries of product characteristics (SmPCs) of drugs with the same active ingredients: an evaluation of SmPCs of the most frequently prescribed active substances. European Journal of Clinical Pharmacology, 2021, , 1.	1.9	0